The attendee will be able to:

1. Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
2. Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
3. List no fewer than 3 study characteristics that influence a decision to use a direct to patient strategy and why they should be considered.